Flag of the European Union EU Clinical Trials Register Help

Clinical trials for ,PrN

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44394   clinical trials with a EudraCT protocol, of which   7406   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    268 result(s) found for: ,PrN. Displaying page 1 of 14.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-001781-15 Sponsor Protocol Number: IOBA-04-2012 Start Date*: 2012-07-31
    Sponsor Name:IOBA, Universidad de Valladolid
    Full Title: Initial protocol setting for the treatment of choroidal neovascularization associated to myopia magna with intravitreal bevacizumab: 3 vs 1 (BENEMCOR.es study)
    Medical condition: choroidal neovascularization associated to myopia magna
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002427-15 Sponsor Protocol Number: 105910 Start Date*: 2015-06-01
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, partially double-blind clinical trial to evaluate the immu-nogenicity and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ combined DTPa-HBV-IPV/Hib vaccine (new formulation) as co...
    Medical condition: Primary immunization of healthy infants in the first year of life against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis diseases and, if applicable, Haemophilus influenzae type b disease.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-003324-20 Sponsor Protocol Number: 114386 Start Date*: 2015-06-10
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: An open-label study to assess the immune persistence in healthy Chinese toddlers primed in infancy with three doses of GSK Biologicals’ DTPa-IPV/Hib vaccine, and to assess the safety and immunogeni...
    Medical condition: Booster immunisation of healthy children in the second year of life against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) diseases.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-004304-19 Sponsor Protocol Number: 117119 Start Date*: 2015-07-23
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa™ vaccine when administered to healthy infants as primary v...
    Medical condition: Active immunization against diphtheria, tetanus, pertussis infection caused by all known subtypes of hepatitis B virus, poliomyelitis, and invasive disease caused by Haemophilus influenzae type B (...
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-001507-31 Sponsor Protocol Number: 111535 Start Date*: 2015-06-09
    Sponsor Name:GlaxoSmithKline Biologicals - GSK China Vaccines
    Full Title: A phase IIIb, open-label, multicentre study to assess the safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ combined diphtheria-tetanus-acellular pertussis (DTPa)- Haemophilus influen...
    Medical condition: Healthy volunteers (Booster immunisation of healthy children in the second year of life against diphtheria, tetanus, pertussis and Haemophilus influenzae type b diseases).
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-001530-25 Sponsor Protocol Number: 208109/232 Start Date*: 2015-06-25
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase IIIb, open, randomized, controlled, multicenter study of the immunogenicity and safety of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine (Havrix) [720 El.U/ 0.5 mL dose] admin...
    Medical condition: Active immunization against hepatitis A, , diphtheria, tetanus, pertussis and Haemophilus influenza type B infections of healthy children 15 months of age at the time of the first study vaccination.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-002946-11 Sponsor Protocol Number: 111852 Start Date*: 2015-05-22
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb, open label, randomized, multicenter study of the im-munogenicity and safety of a booster dose of Kinrix when co-administered with varicella vaccine (Varivax®, Merck and Company) and M...
    Medical condition: Booster immunization of healthy children 4-6 years of age against diphtheria, tetanus, pertussis and polio diseases.
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-002428-34 Sponsor Protocol Number: 110478 Start Date*: 2015-04-30
    Sponsor Name:GlaxoSmithKline Biolgicals
    Full Title: A phase IV, partially double-blind, multicentre study to assess the immunogenicity and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ combined DTPa-HBV-IPV/Hib vaccine (new formulation) as co...
    Medical condition: Booster immunisation of healthy children against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b diseases.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-004133-17 Sponsor Protocol Number: A5I15 Start Date*: 2006-01-19
    Sponsor Name:Sanofi Pasteur Incorporated
    Full Title: A randomised, controlled, double blind study of the immunogenicity and safety of Pediacel™, a combined diphtheria, tetanus, five component acellular pertussis, inactivated poliomyelitis and Haemoph...
    Medical condition: PEDIACEL® is a fully liquid combination vaccine indicated for infants from 2 months of age to protect against diseases caused by 5 common pathogens: Haemophilus influenzae type b, Corynebacterium d...
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003597-26 Sponsor Protocol Number: 1698-302-007 Start Date*: 2019-11-07
    Sponsor Name:Allergan Ltd.
    Full Title: An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension
    Medical condition: Open-angle Glaucoma and Ocular Hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10030043 Ocular hypertension PT
    20.0 10015919 - Eye disorders 10030856 Open-angle glaucoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) AT (Prematurely Ended) DE (Ongoing) BE (Completed) ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002426-70 Sponsor Protocol Number: 104005 Start Date*: 2015-06-01
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: Phase III b, open, randomised, multicenter study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated po...
    Medical condition: Primary immunisation of healthy infants in the first year of life against diphtheria, tetanus, pertussis, hepatitis B, polio, Haemophilus influenzae type b diseases.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-002976-41 Sponsor Protocol Number: ZonMW522004008 Start Date*: 2019-07-09
    Sponsor Name:RIVM
    Full Title: ‘Premature infants and maternal pertussis immunization. Is second trimester vaccination beneficial?’
    Medical condition: women in their first trimester of pregnancy
    Disease:
    Population Age: Preterm newborn infants, Newborns, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003405-42 Sponsor Protocol Number: 201532 Start Date*: 2018-01-16
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, open-label, single-group, multi-centre study to assess the immunogenicity, safety and reactogenicity of GSK Biologicals’ combined reduced antigen content diphtheria, tetanus and acellu...
    Medical condition: Healthy volunteers [Booster immunisation against diphtheria, tetanus and pertussis diseases of individuals from age of four years onwards. The study population for this study will include individua...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-003427-10 Sponsor Protocol Number: 111157 Start Date*: 2015-05-04
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, open-label, randomised, multicentre study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ combined DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™) administered to I...
    Medical condition: Primary immunisation of healthy infants in the first year of life against diphtheria, tetanus, pertussis, hepatitis B, polio and Hib diseases.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-002706-46 Sponsor Protocol Number: DE-3.01_SII-Tdap Start Date*: 2020-01-09
    Sponsor Name:Vakzine Projekt Management GmbH
    Full Title: A Phase II/III, Multicenter, Randomized, Observer-blinded, Active Controlled Clinical Study to Assess the Safety and Immunogenicity of the Tetanus, Diphtheria and Acellular Pertussis Vaccine SIIPL ...
    Medical condition: Active booster immunization against tetanus, diphtheria and pertussis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10021431 Immunisations HLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004194-27 Sponsor Protocol Number: 112957 Start Date*: 2015-06-24
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase III, randomized, multicenter study, double-blind for the immunogenicity and consistency evaluation of 3 lots of GSK Biologicals’ Haemophilus influenzae type b (Hib) conjugate vaccine and si...
    Medical condition: Active immunization against Haemophilus influenzae type b starting from 6 weeks of age as a 3-dose primary series with a single booster dose given at 15 to 18 months
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-000898-30 Sponsor Protocol Number: A5I19 Start Date*: 2006-07-05
    Sponsor Name:Sanofi Pasteur Incorporated
    Full Title: Safety and Immunogenicity of Booster Vaccination with PEDIACEL®, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus Influenzae Type b Conj...
    Medical condition: PEDIACEL is a fully liquid combination vaccine indicated for infants and children for the prevention of five infectious diseases (diphtheria, tetanus, pertussis, poliomyelitis and infections caused...
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004137-16 Sponsor Protocol Number: 114260 Start Date*: 2015-05-27
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, randomized, open-label, multicentre study to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline Biologicals’ combined DTPa-IPV/Hib vaccine administered as a three-...
    Medical condition: Primary immunization of healthy infants in the first year of life against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) diseases.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-003661-17 Sponsor Protocol Number: SS01 Start Date*: 2012-11-09
    Sponsor Name:Moorfields Eye Hospital NHS Foundation Trust
    Full Title: A Multicentre Prospective Open-label Randomised Clinical Trial Comparing the Efficacy of Fixed versus PRN dosing of 700 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) in patie...
    Medical condition: Diabetic macular oedema
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10057915 Diabetic macular oedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-011318-22 Sponsor Protocol Number: H6D-EW-LVIJ Start Date*: 2010-05-07
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: Impact of Tadalafil (LY450190) Once a Day or Tadalafil On Demand Compared to Sildenafil Citrate On Demand on Treatment Discontinuation in Patients with Erectile Dysfunction who are Naïve to PDE5 In...
    Medical condition: Erectile Dysfunction
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038604 - Reproductive system and breast disorders 10061461 Erectile dysfunction PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) ES (Completed) FR (Completed) PT (Completed) GB (Completed) GR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Apr 22 21:39:27 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA